Cardiovascular risk profiles in German Air Force pilots.

INTRODUCTION: Cardiovascular disease (CVD) is the leading cause of death in western industrial countries and one of the most frequent causes of sudden incapacitation in flight for pilots. There are limited data available on cardiovascular risk profiles of pilots, and especially military pilots. The aim of this study was to assess the prevalence of cardiovascular risk factors (CVRF) in German military pilots. METHODS: The changing prevalence of CVRF in active military pilots was studied using a cross-sectional survey during two distinct periods, 2007-2009 and 2016-2018. Data collected included sex, body mass index (BMI), smoking status, resting blood pressure, total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides and glucose. The use of antihypertensive drugs, diagnosis of diabetes mellitus and positive family history of myocardial infarction were also captured. Based on these data, the PROCAM (Prospective Cardiovascular Münster) score was calculated. RESULTS: Data from 5353 flight medical examinations were analysed, 3397 from 2007 to 2009, and 1959 from 2016 to 2018. Between the cohorts, age, BMI, total cholesterol, HDL, LDL, glucose and triglycerides increased significantly. The number of pilots on antihypertensive medication decreased significantly. The PROCAM score increased between cohorts from 18 to 23 points predicting a 10-year risk of an acute coronary event of <1% and 1.3%, respectively. CONCLUSION: The German military pilot population has become older with increased CVRF. CVD will be a future challenge for the German Armed Forces and probably other military forces. However, there was only a mild increase of the PROCAM score over time.

[Diagnosis of fibromatosis colli via color-coded duplex sonography in 13 infants]. / Diagnose der Fibromatosis colli mit der farbkodierten Duplexsonografie bei 13 Säuglingen.

AIM: Fibromatosis colli is the most common cause of congenital torticollis. Patients show a solid tumor in the region of the sternocleidomastoid muscle which has to be differentiated from other congenital space-occupying lesions in the cervical region. PATIENTS AND METHOD: 13 infants (7 boys, 6 girls) with a mean age of 28 +/- 21 days with fibromatosis colli were examined with a high-resolution linear transducer via color-coded duplex sonography. The location of the tumor within the sternocleidomastoid muscle, delineation from surrounding structures, the echogenicity, and the vascularization were estimated. 3 tumors were surgically removed, and the other 10 infants were treated conservatively with physiotherapy. RESULTS: The tumors were located on the right side in 10 patients and on the left side in 3 infants. In 10 patients the tumor was located in the caudal part, in 3 in the middle part of muscle. All tumors showed a good delineation from the surrounding structures. The volume of the tumor was 5.4 +/- 2.7 ml. 8 tumors showed inhomogeneous echogenicity, and 5 showed homogenous echogenicity. 9 tumors had echopoor, 3 echogenic, 1 isoechogenic internal echoes compared to the contralateral healthy muscle. 13 tumors showed increased perfusion (10 diffusely, 3 focally) via color-coded Doppler sonography. CONCLUSION: Diagnosis of fibromatosis colli can be affirmed sonographically. The tumors are commonly located in the distal 2 / 3 of the sternocleidomastoid muscle and show good delineation from surrounding structures. Typically an inhomogeneous, echopoor tumor with increased perfusion can be shown. Additional diagnostic imaging modalities are usually not necessary. The treatment of choice is physiotherapy. In special cases with a lack of improvement, surgery is necessary.

[Cooled tip ablation of left ventricular outflow tract tachycardia through the aortic sinus of valsalva]. / Gekühlte HF-Stromkatheterablation epikardialer Ausflusstrakttachykardien über die Sinus valsalvae der Aorta.

BACKGROUND: Monomorphic tachycardia with an epicardial site of the arrhythmic focus in the left ventricular outflow tract (LVOT) usually cannot be ablated by an endocardial approach. We describe the use of cooled tip catheter ablation through the aortic sinus of valsalva to treat LVOT tachycardia. METHODS: In seven patients (four males, one with valvular cardiomyopathy, six patients without heart disease) with sustained and non-sustained ventricular tachycardia (VT) an epicardial focus of LVOT tachycardia could be identified by pace-mapping and earliest local activation within the aortic sinus of valsalva. Coronary angiography served to define the position of the coronary arteries with respect to the ablation catheter. High frequency current was delivered using a closed-loop cooled tip catheter system (Chilli Cool(R), Boston Scientific). ECG, Holter-ECG, echocardiography and transesophageal echocardiography were performed after the procedure and 3 months later. RESULTS: Foci were located in the left (two patients), in the right (three) and in the a coronary aortic sinus (two). Successful ablation could be achieved in six patients. No procedure-related complications could be observed during a mean follow-up of 4.2 months. CONCLUSION: Monomorphic VT with epicardial origin in the LVOT can be successfully treated by cooled tip ablation through the aortic sinus of valsalva. The use of a cooled tip ablation system may be favourable in several ways: 1) it allows the creation of deep lesions necessary to reach remote foci; 2) due to lower temperatures at the catheter/tissue interface surface tissue damage may be reduced; 3) lower catheter temperature may additionally reduce the risk of local clot formation which is crucial for all left-sided procedures and especially for ablation in the sinus of valsalva.

[Clinical characteristics of patients with AV-nodal reentrant tachycardia (AVNRT): modification by high frequency catheter ablation. Study of 748 patients after high frequency catheter ablation]. / Klinische Charakteristika von Patienten mit AV-Knoten-Reentrytachykardie (AVNRT): Beeinflussung durch die Hochfrequenzkatheterablation. Untersuchung an 748 Patienten nach Hochfrequenzkatheterablation.

AIM: The aim of the study was to analyze the medical history of patients with AV-nodal reentry tachycardia (AVNRT). PATIENTS AND METHODS: Between 1990 and 1999 radiofrequency catheter ablation was performed in 1,024 patients suffering from AVNRT. Data of the previous history were comprehended by questionnaire. RESULTS: 748 (73%) patients replied to the questionnaire. The interval between the first appearance of the symptoms and the catheter ablation was 4.1 +/- 1.5 years. The mean age of the patients was 55.4 years (female) and 58.7 years (male). Merely 6% of all patients had a structural heart disease. The mean duration of case history was 16.8 years. In comparison to the male patients, the assignment for female patients to catheter ablation was after a significant 7 years longer lasting anamnesis. The distribution of age showed that the first tachycardia appeared in 16% of the female patients older than 50 years of age and only in 17% younger than 20 years of age; the corresponding percentages for men were 31% and 18%. With reference to the duration of the longest tachycardia episodes and arrhythmia-related presyncopes and syncopes, women showed a more defined symptomatic. On 20% of the patients a radiofrequency catheter ablation ensued without previous antiarrhythmic treatment; 80% of the patients were treated with 2.8 different antiarrhythmic medications. Medical consultations regarding AVNRT were named as follows (mean/range): family doctor 6.1/1-250, emergency physicians 1.1/0-15, hospital 1.0/0-20. The indication for catheter ablation was set by the family doctor in 13% and by the cardiologist in 77%. Patients got their information about catheter ablation in 2.9% from acquainted persons or news services. CONCLUSION: There is no "typical" anamnesis of AVNRT patients. There is an amazingly high rate of patients with an AVNRT begin in elder stage of age and the fact of therapy delay of 7 years in behalf of women.

Left ventricular leads used in cardiac resynchronization therapy for heart failure patients.

Cardiac resynchronization therapy (CRT) has been introduced as a treatment for selected heart failure patients, specifically those with symptomatic heart failure, left ventricular (LV) dysfunction, and intraventricular conduction delays. CRT is delivered by use of an implanted device and leads positioned in the right atrium, right ventricle, and left ventricle. In the early stages of CRT development, researchers affixed epicardial electrodes to the left ventricle by means of subxiphoid, thoracoscopic, or major surgical procedure. Currently there are a number of transvenous LV leads available that have undergone substantial evaluation. Reports indicate that such leads can be positioned safely by cannulating the coronary sinus and inserting the lead into the venous system. The leads are reported to have acceptable pacing/sensing thresholds and complication rates. Because of individual variations in the cardiac and venous anatomy, as well as sharp angulations in the venous system, maneuverability is an important consideration in lead selection.

Expression and enhanced secretion of proteochondroitin sulphate in a metastatic variant of a mouse lymphoma cell line.

Even though many studies suggest that proteoglycans with their structurally determinative polysaccharide chains, the glycosaminoglycans (GAGs), are important mediators of cellular interactions, little is known about expression and possible functions of these macromolecules expressed by tumour cells during the transition from low to highly metastatic behaviour. Therefore, we investigated the cellular expression and secretion of GAGs in a syngeneic tumour system of DBA/2 mice consisting of a methylcholanthrene-induced low metastatic T lymphoma (Eb), its highly metastatic spontaneous variant (ESb), and a low metastatic derivative of ESb (ESb-MP), selected by its adherent growth properties. The [35S]-sulphate-labelled GAGs were isolated from in vitro cultivated cells and further characterized by separation on Sepharose CL 6B, on Mono-Q ion exchange chromatography, and alkali- and enzymatic digestion. In contrast to Eb-cells which produce chondroitin/dermatan sulphate (CS/DS) and heparan sulphate (HS) (cellular extract: CS/DS 67%, HS 33%; culture medium: CS/DS 61%, HS 39%) ESb- and ESb-MP-cells only express and secrete CS/DS. For ESb cells the CS portions consisted of 42% chondroitin-4-sulphate (CS-4) and 58% chondroitin-6-sulphate (CS-6), for ESb-MP cells of 23% CS-4 and 77% CS-6, for Eb cells of 16% CS-4 and 84% CS-6. The cell surface GAGs of the adherent variant ESb-MP contained a significantly higher portion of DS (65%) compared to ESb cells (25%). GAGs of all tumour cell lines studied had a mol. wt ranging from 35-40 kD compared to GAG molecular weight standards. Ion exchange chromatography indicated that differences in charge density between GAGs of these cell lines were minimal. These findings suggest that the different biological behaviour of the cell lines cannot be attributed to altered size and charge density of their GAG chains. However, highly metastatic ESb-cells secreted significantly more GAG than low metastatic Eb- and ESb-MP-cells. The possible consequences of the enhanced secretion of CS/DS by ESb-cells are discussed in terms of the postulated role of CS/DS in cellular adhesion, growth regulation and interactions with the immune system.